Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts. Show more

Location: 490 Arsenal Way, Watertown, MA, 02472, United States | Website: https://tectonictx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

359M

52 Wk Range

$13.70 - $61.07

Previous Close

$19.18

Open

$19.01

Volume

383,037

Day Range

$19.01 - $20.71

Enterprise Value

91.5M

Cash

268.4M

Avg Qtr Burn

-15.61M

Insider Ownership

38.38%

Institutional Own.

64.97%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.